NANALYSIS SCIENTIFIC CORP (NSCI.CA) Stock Fundamental Analysis
Canada - TSX-V:NSCI - CA63000Y1034 - Common Stock
0.17 CAD
0 (0%)
Taking everything into account, NSCI scores 4 out of 10 in our fundamental rating. NSCI was compared to 16 industry peers in the Health Care Equipment & Supplies industry. NSCI may be in some trouble as it scores bad on both profitability and health. A decent growth rate in combination with a cheap valuation! Better keep an eye on NSCI.
1. Profitability
1.1 Basic Checks
In the past year NSCI has reported negative net income.
NSCI had a positive operating cash flow in the past year.
NSCI had negative earnings in each of the past 5 years.
In the past 5 years NSCI reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -33.34%, NSCI belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
Looking at the Return On Equity, with a value of -99.08%, NSCI belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.34% | ||
| ROE | -99.08% | ||
| ROIC | N/A |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NSCI (28.40%) is worse than 62.50% of its industry peers.
In the last couple of years the Gross Margin of NSCI has declined.
The Profit Margin and Operating Margin are not available for NSCI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
2. Health
2.1 Basic Checks
NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
NSCI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NSCI has been increased compared to 5 years ago.
Compared to 1 year ago, NSCI has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.71, we must say that NSCI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.71, NSCI is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
NSCI has a debt to FCF ratio of 352.74. This is a negative value and a sign of low solvency as NSCI would need 352.74 years to pay back of all of its debts.
NSCI has a better Debt to FCF ratio (352.74) than 93.75% of its industry peers.
A Debt/Equity ratio of 0.72 indicates that NSCI is somewhat dependend on debt financing.
NSCI has a Debt to Equity ratio of 0.72. This is in the better half of the industry: NSCI outperforms 68.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 352.74 | ||
| Altman-Z | -0.71 |
ROIC/WACCN/A
WACC5.7%
2.3 Liquidity
NSCI has a Current Ratio of 0.87. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
NSCI has a Current ratio of 0.87. This is in the better half of the industry: NSCI outperforms 62.50% of its industry peers.
NSCI has a Quick Ratio of 0.87. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NSCI (0.61) is better than 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
NSCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.12%, which is quite good.
The Revenue has grown by 9.01% in the past year. This is quite good.
The Revenue has been growing by 40.32% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)13.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.65%
Revenue 1Y (TTM)9.01%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-16.54%
3.2 Future
Based on estimates for the next years, NSCI will show a very strong growth in Earnings Per Share. The EPS will grow by 36.08% on average per year.
NSCI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.48% yearly.
EPS Next Y81.82%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y36.08%
Revenue Next Year-0.13%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.48%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NSCI. In the last year negative earnings were reported.
NSCI is valuated cheaply with a Price/Forward Earnings ratio of 4.21.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NSCI indicates a rather cheap valuation: NSCI is cheaper than 100.00% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of NSCI to the average of the S&P500 Index (32.68), we can say NSCI is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.21 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NSCI is valued cheaper than 93.75% of the companies in the same industry.
93.75% of the companies in the same industry are more expensive than NSCI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 390.39 | ||
| EV/EBITDA | 48.85 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NSCI's earnings are expected to grow with 45.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.14%
EPS Next 3Y45.9%
5. Dividend
5.1 Amount
NSCI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:NSCI (11/6/2025, 7:00:00 PM)
0.17
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners8.54%
Inst Owner ChangeN/A
Ins Owners3.96%
Ins Owner ChangeN/A
Market Cap19.52M
Revenue(TTM)43.03M
Net Income(TTM)-12.53M
Analysts80
Price Target0.84 (394.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-98.02%
Min EPS beat(2)-98.02%
Max EPS beat(2)-98.02%
EPS beat(4)0
Avg EPS beat(4)-98.02%
Min EPS beat(4)-98.02%
Max EPS beat(4)-98.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.55%
Min Revenue beat(2)-7.95%
Max Revenue beat(2)-7.14%
Revenue beat(4)2
Avg Revenue beat(4)2.32%
Min Revenue beat(4)-7.95%
Max Revenue beat(4)16.28%
Revenue beat(8)5
Avg Revenue beat(8)11.79%
Revenue beat(12)7
Avg Revenue beat(12)5.02%
Revenue beat(16)8
Avg Revenue beat(16)1.86%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.21 | ||
| P/S | 0.45 | ||
| P/FCF | 390.39 | ||
| P/OCF | 10.52 | ||
| P/B | 1.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | 48.85 |
EPS(TTM)-0.06
EYN/A
EPS(NY)0.04
Fwd EY23.76%
FCF(TTM)0
FCFY0.26%
OCF(TTM)0.02
OCFY9.5%
SpS0.37
BVpS0.11
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.34% | ||
| ROE | -99.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.4% | ||
| FCFM | 0.12% |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
F-Score5
Asset Turnover1.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 352.74 | ||
| Debt/EBITDA | 12.75 | ||
| Cap/Depr | 42.03% | ||
| Cap/Sales | 4.19% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 261.64% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z | -0.71 |
F-Score5
WACC5.7%
ROIC/WACCN/A
Cap/Depr(3y)97.82%
Cap/Depr(5y)114.88%
Cap/Sales(3y)16.41%
Cap/Sales(5y)20.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.65%
EPS Next Y81.82%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y36.08%
Revenue 1Y (TTM)9.01%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-16.54%
Revenue Next Year-0.13%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.48%
EBIT growth 1Y52.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year178.7%
EBIT Next 3Y72.2%
EBIT Next 5Y55.02%
FCF growth 1Y100.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y113.25%
OCF growth 3YN/A
OCF growth 5Y33.1%
NANALYSIS SCIENTIFIC CORP / NSCI.CA FAQ
What is the ChartMill fundamental rating of NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to NSCI.CA.
What is the valuation status for NSCI stock?
ChartMill assigns a valuation rating of 7 / 10 to NANALYSIS SCIENTIFIC CORP (NSCI.CA). This can be considered as Undervalued.
How profitable is NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?
NANALYSIS SCIENTIFIC CORP (NSCI.CA) has a profitability rating of 2 / 10.
What is the expected EPS growth for NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?
The Earnings per Share (EPS) of NANALYSIS SCIENTIFIC CORP (NSCI.CA) is expected to grow by 81.82% in the next year.